JP2010013395A - Prophylactic or ameliorant for metabolic syndrome symptom - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a preventive or ameliorating agent for metabolic syndrome that prevents and improves hypertension and / or lipid metabolism abnormality.
A preventive or ameliorating agent for metabolic syndrome, comprising isomaltulose as an active ingredient, for preventing or ameliorating a metabolic syndrome or a symptom of suspected metabolic syndrome.
[Selection figure] None

Description

  The present invention relates to a preventive or ameliorating agent for metabolic syndrome symptoms.

  Metabolic syndrome refers to a state in which various diseases are easily caused by visceral fat accumulated excessively, and is also called “visceral fat syndrome”.

  Recently, it has been found that some important physiologically active substances (adipocytokines) are secreted from adipocytes, greatly affecting various functions of the body. If visceral fat accumulates excessively, adipocytokines are abnormally secreted, and blood sugar level, neutral fat, blood pressure and / or cholesterol may increase, resulting in lifestyle diseases such as diabetes, hypertension and hyperlipidemia. It is said to cause. Because lifestyle-related diseases are closely related to each other, even if individual lifestyle-related diseases are mild, if they are left as they are, they can be combined to promote arteriosclerosis, and life-related diseases such as myocardial infarction and cerebral infarction Can be a factor.

So far, fat composition containing diacylglycerol having an effect of suppressing body fat accumulation (Patent Document 1), liquid food containing indigestible dextrin that suppresses an increase in blood glucose level (Patent Document 2), person with high blood pressure A food material containing γ-aminobutyric acid suitable for food (Patent Document 3) and the like are known.
JP 2005-336471 A JP 2000-189109 A JP-A-7-213252 JP 2004-315499 A JP 2006-306831 “Starch Science”, Vol. 35, No. 2, 1988, p. 131-139 “Hormone and Metabolic Research”, 1989, Vol. 21, p. 338-340

  Against this background, there is a need for new substances that can prevent and improve metabolic syndrome by preventing and improving hypertension and / or serum lipid abnormalities. Therefore, an object of the present invention is to provide a preventive or ameliorating agent for metabolic syndrome that prevents and improves hypertension and / or serum lipid abnormality.

  The present invention relates to a preventive or ameliorating agent for metabolic syndrome comprising isomaltulose as an active ingredient, that is, preventing or improving a metabolic syndrome or a symptom of suspected metabolic syndrome comprising isomaltulose as an active ingredient. Provide the agent.

  Moreover, it is preferable that the preventive or ameliorating agent for metabolic syndrome symptoms of the present invention is for preventing and improving hypertension and / or for preventing and improving abnormal serum lipids.

  According to the preventive or ameliorating agent for metabolic syndrome of the present invention, it is possible to prevent and improve hypertension and / or serum lipid abnormality in a person (subject) with metabolic syndrome or a person (subject) suspected of having metabolic syndrome. As a result, symptoms of lifestyle-related diseases such as hypertension and hyperlipidemia can be prevented and improved, thereby preventing or improving metabolic syndrome symptoms.

  It is known that palatinose has a slow hydrolysis rate of about 1/6 that of sucrose and maintains blood glucose and insulin concentrations at a constant level for a long time after ingestion (Non-patent Documents 1 and 2). In addition, it has been reported that palatinose suppresses an increase in blood sugar level due to intake of carbohydrates and suppresses body fat accumulation due to an increase in blood sugar level and insulin secretion (Patent Document 4). Furthermore, it has been reported that palatinose inhibits sucrase activity and glucoamylase activity (Patent Document 5). Note that sucrase is an enzyme that degrades sucrose, and glucoamylase is an enzyme that degrades the α-1,4 bond at the non-reducing end of the sugar chain to produce glucose.

  Thus, palatinose has been known to play an important role in relation to carbohydrate degradation / absorption and blood glucose level regulation, but in subjects with metabolic syndrome and / or subjects with suspected metabolic syndrome It has not been known so far that palatinose affects hypertension and / or serum lipid abnormalities.

  The present inventors have now found a new palatinose attribute that it is possible to prevent and ameliorate metabolic syndrome symptoms in a subject by ingesting palatinose in a subject with metabolic syndrome or a subject suspected of having metabolic syndrome. . The present inventors indicate that this attribute makes it suitable for use as a preventive or ameliorating agent for metabolic syndrome in order to ameliorate and / or prevent metabolic syndrome symptoms in subjects with metabolic syndrome or subjects suspected of having metabolic syndrome. I found it.

  Furthermore, the preventive or ameliorating agent for metabolic syndrome of the present invention is preferably taken for a predetermined period or more with a predetermined amount of palatinose per day. What is necessary is just to adjust palatinose content suitably on the basis of per adult, and 5-60g per day is preferable, 7-50g is more preferable, 7-40g is still more preferable. Moreover, it is preferable to ingest palatinose instead of the whole amount or a part of sucrose normally ingested. In the subject of metabolic syndrome, the predetermined period during which palatinose is ingested is preferably 1 month or longer, more preferably 2 months or longer, even more preferably 3 months or longer, and still more preferably 4 months or longer. In addition, in a subject suspected of having metabolic syndrome, the predetermined period during which palatinose is ingested is preferably 1 month or longer, more preferably 2 months or longer, and even more preferably 3 months or longer.

  According to the above-mentioned preventive or ameliorating agent for metabolic syndrome, the effect of preventing and improving hypertension and / or serum lipid abnormality caused by palatinose can be continuously maintained, so that metabolic syndrome can be further prevented and improved. It is possible to maintain a state of preventing and improving syndrome symptoms.

  According to the preventive or ameliorating agent for metabolic syndrome of the present invention, hypertension and / or serum lipid abnormality can be prevented and improved. By preventing and improving metabolic syndrome symptoms, the risk of myocardial infarction and cerebral infarction can be reduced.

  Hereinafter, preferred embodiments of the present invention will be described in detail.

  In the present invention, “isomaltulose” is a disaccharide constituted by α-1,6-glucosyl bonding of glucose to fructose, and is also referred to as “palatinose”. “Palatinose” and “palatinose” are registered trademarks of Mitsui Sugar Co., Ltd.

The palatinose may be a hydrate. In the case of the monohydrate, the melting point is 123 to 124 ° C., and the specific rotation is [α] ²⁰ _D +97.0 to 99.0 (C = 0.04). ) Ferring solution reducing power is 52% of glucose and solubility in 100 g of water is 38.4 g at 20 ° C. Moreover, the sweetness quality of the aqueous solution is good, and the sweetness is about 40% of sucrose.

  Palatinose is found in honey in nature. Moreover, it exists also in the transfer product produced when (alpha) -glucosyltransferase (isomalulose synthase) derived from bacteria and yeast acts on sucrose.

  Industrially, palatinose is produced by allowing sucrose to act on α-glucosyltransferase derived from bacteria such as Protaminobacter rubrum and Serratia plymutica.

  The preventive or ameliorating agent for metabolic syndrome in the present invention is a preventive or ameliorating agent containing palatinose as an active ingredient, and is used for preventing and improving the symptoms of a subject of metabolic syndrome or a subject suspected of having metabolic syndrome. .

  In the present invention, a person (person) corresponding to the “metabolic syndrome definition and diagnostic criteria” described below is treated as a target of the metabolic syndrome. In addition, those who are not metabolic syndrome but who fall into any one or more of the visceral fat type obesity, hyperglycemia, hypertension and serum lipid abnormality in “Definitions and diagnostic criteria of metabolic syndrome” Treat as a suspicious object. In addition, subjects suspected of having metabolic syndrome in the present invention include hypercholesterolemia, hyper-LDL-cholesterolemia, hypo-HDL-cholesterolemia, and hypertriglyceremia that are one or more of hyperlipidemia. Applicable persons are also included. In addition, if it is a person who corresponds to the said conditions, it will treat not only as a Japanese but the object of the metabolic syndrome in this invention, or the object which is suspected of the metabolic syndrome.

“Definition of metabolic syndrome and diagnostic criteria” is a Japan-specific standard announced at the 102nd Annual Meeting of the Japanese Society of Internal Medicine (held in April 2005). According to this, in addition to “Accumulation of visceral fat” When two or more of the other three items are applicable, “metabolic syndrome” is diagnosed. When the visceral fat area in the abdominal section is 100 cm ² or more, it is regarded as “accumulation of visceral fat”. However, since it is not easy to directly measure the visceral fat area in health checkups and daily clinical settings, it is substituted by measuring the abdominal girth, when the abdominal circumference is 85 cm or more and the female is 90 cm or more. It is diagnosed as visceral fat obesity corresponding to “accumulation”. The other three items are as follows.
1. 1. Hyperglycemia: Fasting blood glucose of 110 mg / dL or more 2. Hypertension: systolic blood pressure 130 mmHg or higher and / or diastolic blood pressure 85 mmHg or higher Serum lipid abnormality: serum neutral fat of 150 mg / dL or more and / or serum HDL cholesterol level of less than 40 mg / dL

  Hypertension is one of lifestyle-related diseases. According to the standards of the World Health Organization (WHO), hypertension is determined when the systolic blood pressure is 140 mmHg or higher and / or the diastolic blood pressure is 90 mmHg or higher. In addition, when it corresponds to the standard of this hypertension, it corresponds also to the standard of the hypertension of the above-mentioned "metabolic syndrome definition and diagnostic standard".

  Examples of serum lipids include total cholesterol, HDL cholesterol, LDL cholesterol, and neutral fat (triglyceride). Hypercholesterolemia, high LDL cholesterolemia, low HDL cholesterolemia and hypertriglyceremia are collectively referred to as hyperlipidemia. According to the Arteriosclerotic Disease Clinical Practice Guidelines (2002), hypercholesterolemia is a type of hyperlipidemia in which a lot of total cholesterol is present in blood (220 mg / dL or more). High LDL cholesterolemia is a type of hyperlipidemia in which a large amount of LDL cholesterol (so-called bad cholesterol) is present in blood (140 mg / dL or more), and low HDL cholesterolemia is HDL cholesterol in blood. It is a type of hyperlipidemia with less (so-called good cholesterol) (less than 40 mg / dL). Hypertriglyceremia is a type of hyperlipidemia in which a large amount of neutral fat is present in blood (150 mg / dL or more). These measured values are based on serum lipid values collected on fasting blood.

  The term “serum lipid abnormality” as used herein refers to a case corresponding to one or more of the above hyperlipidemias. In addition, the serum lipid abnormality in the above “definitions and diagnostic criteria of metabolic syndrome” corresponds to hypoHDLemia and / or hypertriglyceremia among hyperlipidemias.

  The “prophylactic improvement of metabolic syndrome symptoms” broadly means to improve and / or prevent metabolic syndrome symptoms. Specifically, visceral fat type obesity, hyperglycemia, hypertension and serum lipid abnormalities, In addition, it means improving and / or preventing one or more symptoms of hyperlipidemia.

  In the present invention, “prevention / improvement of metabolic syndrome symptoms” means, in a narrow sense, improvement and / or prevention of metabolic syndrome symptoms by improvement and / or prevention of hypertension and / or serum lipid abnormality.

  The “hypertension improvement” specifically refers to a case where the systolic blood pressure and / or the diastolic blood pressure decreases, and in addition to a case where the diagnostic reference value (abnormal value) decreases to a normal value. “Prevention of hypertension” refers to the case of preventing an increase from a normal value to a diagnostic reference value in addition to preventing an increase in systolic blood pressure and / or diastolic blood pressure.

  In the present invention, “serum lipid abnormality improvement” specifically refers to measurement of one or more of triglyceride, total cholesterol and LDL cholesterol, or increases in HDL cholesterol. When the value changes from the diagnostic reference value (abnormal value) to the normal value. In addition, “serum lipid abnormality prevention” refers to preventing the increase of one or more measured values of neutral fat, total cholesterol, and LDL cholesterol, or preventing the decrease of HDL cholesterol. This refers to the case where the measured value is prevented from changing from a normal value to a diagnostic reference value.

  Moreover, “visceral fat type obesity improvement” refers to a case where the visceral fat area and / or abdominal circumference decreases, and also a case where the standard value (abnormal value) decreases to a normal value. Further, “visceral fat type obesity prevention” refers to a case of preventing an increase in the visceral fat area and / or abdominal circumference from a normal value to a diagnostic reference value.

  In addition, “hyperglycemia improvement” refers to a case where the fasting blood glucose is reduced, and in addition, the diagnosis reference value (abnormal value) is reduced to a normal value. “Prevention of hyperglycemia” refers to a case of preventing an increase from a normal value to a diagnostic reference value in addition to preventing an increase in fasting blood glucose.

  The preventive or ameliorating agent for metabolic syndrome of the present invention only needs to contain palatinose as an active ingredient, and may be composed of palatinose alone or a mixture of palatinose and other components. Examples of other components include known pharmaceutically acceptable excipients and carriers, and in addition to these, sucrose, wheat flour, starch, dextrin, isomerized sugar, and the like may be included.

  Moreover, you may use the mixture which combined the palatinose with the other carbohydrate which is a non-reducing sugar as said prevention or improvement agent. Thereby, the cause of coloring decreases and it becomes difficult to color food. Further, palatinose may be combined with other carbohydrates having good solubility. This makes it difficult to crystallize.

  Palatinose may be used in combination with sweeteners such as sucrose and isomerized sugar. As a result, the sweetness of sucrose, glucose, and isomerized sugar is reduced, and a refreshing, low-sweet food can be produced.

  Moreover, as said prevention or improvement agent, crystalline palatinose, palatinose syrup, or trehalulose syrup can be used, for example. Crystalline palatinose (trade name “Crystalline palatinose IC”, manufactured by Mitsui Sugar Co., Ltd.) contains 99.0% or more of palatinose (crystal-containing water). Palatinose syrup (trade names “palatinose syrup-ISN” and “palatinose syrup-TN” manufactured by Mitsui Sugar Co., Ltd.) contains 11-17% palatinose and 53-59% trehalulose. Trehalulose syrup (trade names “Mildia-75” and “Mildia-85”, manufactured by Mitsui Sugar Co., Ltd.) contains 8-13% palatinose and 83-89% trehalulose.

  Although the shape of said prevention or improvement agent will not be specifically limited if palatinose is included as an active ingredient, For example, a fondant, a granule, a tablet confectionery (tablet), a syrup agent, a drink agent, a powder mixture etc. are mentioned. Further, the preventive or ameliorating agent for metabolic syndrome of the present invention is a food for specified health use, functional food, health food, quasi drug, and a material usable for food, quasi drug and medicine. It can be processed into pharmaceutical products.

  The amount of palatinose contained in the preventive or ameliorating agent is preferably 5 g or more, more preferably 7 g or more, and still more preferably 10 g or more. The palatinose content is preferably 60 g or less, more preferably 50 g or less, even more preferably 45 g or less, and even more preferably 40 g or less.

  As a method for ingesting the above preventive or ameliorating agent, oral ingestion can be mentioned. Moreover, it is preferable to ingest palatinose instead of the whole amount or part of the sucrose normally ingested, and palatinose may be ingested in place of a part of the normally ingested carbohydrate. Examples of sugars other than sucrose include glucose, fructose, isomerized sugar, dextrin, branched dextrin, starch and the like. When ingested simultaneously with carbohydrates, palatinose: sucrose = 10: 90 to 99: 1 is preferable, 30:70 to 99: 1 is more preferable, and 50:50 to 90:10 is still more preferable.

  Palatinose is broken down by isomaltase in the small intestine to produce glucose and fructose. These monosaccharides are absorbed and metabolized from the small intestine in the same manner as when sucrose is degraded by enzymes. Therefore, palatinose has a calorie of 4 kcal / g like sucrose, and becomes an energy source and an essential material for glycogen, sugar chain and the like for cells to function normally. Therefore, palatinose can be ingested as a saccharide source instead of saccharides such as sucrose, glucose, fructose, isomerized sugar, dextrin, branched dextrin and starch. Moreover, palatinose does not show gastrointestinal disorders such as laxative action or abdominal bloating. Furthermore, since the hydrolysis rate of palatinose is as low as 1/6 of sucrose, the blood glucose level and insulin concentration after ingestion can be maintained at a constant level for a long time.

  The intake period of the preventive or ameliorating agent of the present invention is preferably 1 month or more, more preferably 2 months or more, still more preferably 3 months or more, and still more preferably 4 months or more, in the subject of metabolic syndrome. In addition, in a subject suspected of having metabolic syndrome, 1 month or longer is preferable, 2 months or longer is more preferable, and 3 months or longer is even more preferable. In addition, the intake frequency per week is preferably 3 days or more, more preferably 4 days or more, still more preferably 5 days or more, still more preferably 6 days or more, and most preferably 7 days.

  Hereinafter, preferred examples of the present invention will be described in more detail, but the present invention is not limited to these examples.

Example 1
The following tests were conducted with Japanese Americans in Brazil as subjects. In addition, it is thought that Japanese Nikkei in Brazil has a high risk of lifestyle-related diseases and is ahead of the situation 20 to 30 years ahead of the Japanese. First, in accordance with the Declaration of Helsinki, with the consent of the person concerned, men who were diagnosed with metabolic syndrome among the men who were found to be eligible by the investigator were selected as subjects. Based on age and medication status, subjects were randomly divided into two groups (test group and control group) and a double-blind placebo-controlled study was performed. There were 6 subjects in the test group with an average age of 58.8 years, while 7 subjects in the control group had an average age of 61.4 years. Granule sugar granulated with the formulation shown in Table 1 was used as a test meal to be provided to subjects in the test group, and granule sugar granulated from sucrose was used as a control meal to be provided to subjects in the control group. The intake method was used instead of sugar when daily sugar was used, and the intake was free. When calculated from the amount used at the end of the study, the average daily intake per person in both groups was 45 g. A test meal or a control meal was ingested for 4 months, and the items shown in Table 2 were examined before and after ingestion. Table 2 shows the results of the medical examination.

有意差（ｖｓ試験前値）
＃：ｐ＜０．１ ＊：ｐ＜０．０５ ＊＊：ｐ＜０．０１

Significant difference (vs pre-test value)
#: P <0.1 *: p <0.05 **: p <0.01

Here, BMI (body mass index) is an index representing the degree of obesity, and is represented by the following equation.
BMI = weight (kg) / height (m) ²

  HbA1c is a ratio (normal value: 4.4 to 5.8%) of glucose (blood glucose) bound to hemoglobin A (HbA), and is an average blood glucose level for the past 1 to 1.5 months from the present time. It is an indicator.

  In the test group, BMI, body weight, body fat, trunk fat, systolic blood pressure, diastolic blood pressure, total cholesterol and LDL cholesterol were statistically significantly decreased before and after the test, and also for visceral fat and neutral fat. A decreasing trend was observed. In the control group, systolic blood pressure, total cholesterol and HbA1c were significantly reduced before and after the test.

  From the above results, it was found that BMI, body weight, body fat, trunk fat and the like can be reduced and metabolic syndrome can be improved by ingesting palatinose instead of sucrose which is normally ingested. In addition, it was found that diastolic blood pressure can be reduced and systolic blood pressure can be reduced as compared with the control, so that hypertension can be improved. Furthermore, LDL cholesterol and triglycerides can be reduced, and the total cholesterol level can be reduced as compared with the control. Thus, it has been found that serum lipid abnormality can be improved.

(Example 2)
Subjects who were Japanese (woman and man) over 40 years old and suspected of having metabolic syndrome, that is, a man whose abdominal circumference was 85 cm or more and a woman whose abdominal circumference was 90 cm or more were used as subjects. In accordance with the Declaration of Helsinki, the subjects were those who were approved by the investigator after obtaining their consent. The subjects were examined by the WHO CARDIAC system and urine was collected for 24 hours, and a randomized clinical trial was conducted. The subjects were randomly divided into two groups (test group and control group) based on age, medication status, etc., and a double-blind placebo-controlled study was performed. The test group had 6 females and 4 males with an average age of 49.0 years, and the control group had 4 females and 5 males with an average age of 47.3 years. The subjects took the sample meal shown in Table 3. In addition, as a saccharide | sugar mix | blended with the sample food of Table 3, the mixture of palatinose: sucrose = 1: 1 was used in the test group, while only sucrose was used in the control group. In addition, both the test group and the control group were ingested any two types of sample food per day so that the carbohydrate intake of the sample food per day was 40 g. The average sugar intake of the sample meal per person per day was 40 g in the test group and 38 g in the control group. The test which takes sample food for 3 months was done, and the medical examination was performed about the item shown in Table 4 before and after the test. Table 4 shows the results of the medical examination.

有意差（ｖｓ試験前値）
＃：ｐ＜０．１ ＊：ｐ＜０．０５ ＊＊：ｐ＜０．０１

Significant difference (vs pre-test value)
#: P <0.1 *: p <0.05 **: p <0.01

Here, HOMA-R (Homeostasis Model Assessment Insulin Resistance Index) is an index representing insulin resistance and is represented by the following formula.
HOMA-R = Fasting blood glucose (mg / dl) × Fasting blood insulin concentration (μU / ml) ÷ 405

  In the test group, systolic blood pressure, diastolic blood pressure, total cholesterol and fasting blood glucose were statistically significantly decreased before and after the test, and HbA1c was significantly increased. On the other hand, in the control group, subcutaneous fat decreased significantly before and after the test, visceral fat, total cholesterol and HbA1c increased significantly, and neutral fat and HOMA-R showed an increasing trend.

  In the control group of Example 2, visceral fat is accumulated and neutral fat and HOMA-R are increased. From this result, it can be seen that the risk of metabolic syndrome is increased in the control group of Example 2. This indicates that the test condition of the control group of Example 2 is a condition for ingesting a larger amount of carbohydrate than the normal carbohydrate intake of Japanese, and a condition for causing metabolic syndrome ( In addition, since Japanese Brazilians use a lot of sugar everyday, the intake of carbohydrates in Example 1 is a normal amount for Japanese Brazilians).

  Thus, despite the excessive intake of carbohydrates, visceral fat was not accumulated and neutral fat and HOMA-R were not increased in the test group. That is, it was found that metabolic syndrome caused by excessive intake of sucrose can be prevented by ingesting palatinose. Specifically, it was found that metabolic syndrome caused by excessive intake of sucrose can be prevented by replacing half of sucrose with palatinose.

  It was also found that taking palatinose can suppress increases in systolic blood pressure and diastolic blood pressure, but rather can reduce systolic blood pressure and diastolic blood pressure. Therefore, it was found that high blood pressure can be prevented. Furthermore, it was found that the increase in the total cholesterol amount can be suppressed, and rather the total cholesterol amount can be reduced. Therefore, it was found that serum lipid abnormality can be improved. These facts also suggest that palatinose may act to suppress the adverse effects on metabolic syndrome caused by sucrose, which accounts for half of the sugar in the sample food.

(Example 3)
The following tests were conducted with Japanese subjects who satisfy the following selection criteria and exclusion criteria as subjects. The study was conducted in strict accordance with ethical principles based on the Declaration of Helsinki and the "Ethical Guidelines for Epidemiological Research (MEXT, Ministry of Health, Labor and Welfare)".

Selection criteria are: 1) normal male over 35 years old or post-menopausal female (no menstruation over 1 year) 2) BMI over 25 kg / m ² 3) abdominal circumference over 85 cm or abdominal circumference over 90 cm 4) Women suspected of having metabolic syndrome (i. Fasting blood glucose 110 mg / dl or higher, ii. Neutral fat 150 mg / dl or higher, or HDL cholesterol 40 mg / dl or lower, iii. Systolic blood pressure 130 mmHg or higher or diastole Blood pressure of 85 mmHg or higher; those corresponding to one or more of these i to iii), 5) those who are consuming sucrose beverages (coffee, tea, etc.) that use sucrose at breakfast, and 6) food As a habit, a person who ingests about 15 g or more of sugar per day was used.

  Exclusion criteria include: 1) those who currently have a basic disease and are being treated or taken to hospital 2) those who are taking low-calorie sweeteners and / or products using low-calorie sweeteners on a daily basis, 3 ) Persons who regularly use foods and supplements for specific health that affect body fat mass and blood sugar levels, and / or health foods containing food ingredients that have the potential to affect the clinical values 4) Sample food Those who have had allergic symptoms to foods or wheat previously included, or are under treatment, 5) Fasting blood glucose is 126 mg / dl or more, 6) HbA1c is 6.1% or more, etc. It was. Preliminary examinations were performed on subjects judged to be eligible, and subjects with low insulin resistance, blood glucose, and insulin level were selected.

  The selected subjects were divided into two groups, a test group and a control group, and the test was conducted by a double-blind group comparison method. The number of subjects in the test group was 29, and the number of subjects in the control group was 27. The test group subjects received the test meal described below, and the control group subjects received the control diet described below as a substitute for sugar for 3 weeks (15 g) per day for 12 weeks. As a test meal, 2.45 g of palatinose and 2.45 g of sucrose were mixed together, and 2% liquid sugar consisting of fructose and butter sugar was added in one sachet to make it moist as in the case of upper white sugar. A thing was used. As the control food, sucrose 4.9 g was added with 2% liquid sugar consisting of fructose and glucose, and white saccharose packed in one sachet was used. Before and after the test, medical examination was performed on the items shown in Tables 5 and 6. Table 5 shows the medical examination results of the test group, and Table 6 shows the medical examination results of the control group.

有意差（群間）
＃：ｐ＜０．１ ＊：ｐ＜０．０５

Significant difference (between groups)
#: P <0.1 *: p <0.05

  The average abdominal circumference of the test group tended to decrease slightly throughout the entire test period after 4, 8 and 12 weeks. On the other hand, the average abdominal circumference of the subject group tended to increase slightly throughout the test period after 4 weeks and 8 weeks. However, there was no statistically significant difference between the two groups regarding waist circumference.

Regarding the mean visceral fat area value, although no statistically significant difference was observed between the two groups, the test group showed a slight tendency to suppress the increase in visceral fat area compared to the control group. Therefore, the analysis was performed by stratifying the subjects whose visceral fat area before the test was less than 120 cm ² . The analysis results are shown in Table 7. As shown in Table 7, the mean visceral fat area value of the test group decreased from the pre-test, whereas the mean visceral fat area value of the control group increased from the pre-test.

有意差（群間）
＊：ｐ＜０．０５

Significant difference (between groups)
*: P <0.05

  In terms of serum lipids, the average value of HDL cholesterol in the test group was statistically significantly higher than that of the control group in all cases after 4 weeks, 8 weeks and 12 weeks. Indicated. For total cholesterol and LDL cholesterol, there was no statistically significant difference between the two groups. In terms of blood pressure, the systolic blood pressure of the control group was statistically significantly higher than that of the test group after 4 weeks and 12 weeks, respectively. The diastolic blood pressure of the control group was significantly higher than that of the test group after 8 weeks and 12 weeks, respectively. The pulse of the control group was significantly higher than that of the test group after 12 weeks.

  Despite conditions in which blood pressure tends to increase in the control group, systolic blood pressure, diastolic blood pressure and pulse in the test group are significantly lower than those in the control group. It was found that metabolic syndrome caused by ingestion of can be prevented. Therefore, it was found that metabolic syndrome can be prevented by ingesting 7.35 g of palatinose per day. Moreover, it turned out that the effect is high when the metabolic syndrome symptom is mild.

  From the above Examples 1 to 3, it was shown that metabolic syndrome can be improved and / or prevented by ingesting palatinose. It was also found that hypertension and / or serum lipid abnormalities can be improved and / or prevented. Furthermore, it was shown that metabolic syndrome due to excessive intake of sucrose can be prevented.

Example 4
<Stick sugar containing palatinose and sucrose>
The same mass of palatinose and sucrose was mixed, and the stick packaging was filled so that 3.5 g each of palatinose and sucrose was contained per package. The obtained stick sugar is an edible material containing palatinose and sucrose and suitable for the improvement and / or prevention of hypertension and / or serum lipid abnormality.

(Example 5)
<Gum syrup containing palatinose and isomerized sugar>
Gum syrup containing palatinose and isomerized sugar was produced with the formulation shown in Table 8 below. Specifically, palatinose and gum arabic were combined, powder mixed, isomerized sugar and water were added thereto, boiled and mixed, and the resulting solution was adjusted to 30 with Refbrix.

(Example 6)
<Tablets containing palatinose and sucrose>
Tablets, which are foods containing palatinose and sucrose, were produced with the formulations shown in Table 9 below. Specifically, a tablet having a diameter of 18 mm, a thickness of 5 mm, and a mass of 1.5 g was formed by applying a tableting pressure of 300 kg / cm ³ to the mixed powder having the following composition.

(Example 7)
<Powdered beverage containing palatinose and sucrose>
A powdered beverage, which is a food containing palatinose and sucrose, with the formulation shown in Table 10 below, was produced using a universal mixing stirrer according to a conventional method.

(Example 8)
<Soft drinks containing palatinose and sucrose>
Soft drinks containing palatinose and sucrose were prepared according to the formulation shown in Table 11 below. The following raw materials were dissolved in 250 ml of hot water and then filled into beverage cans (for 250 ml).

(Example 10)
<Sponge cake containing palatinose, sugar, and starch>
A sponge cake containing palatinose, sucrose and starch was prepared according to the formulation shown in Table 12 below. A powder mixture of crystalline palatinose, sucrose (granulated sugar) and xanthan gum was designated as A. Separately, B was a mixture of flour and baking powder. In A, milk and Ryotoester SP were added and mixed well. Eggs were put into this, mixed well until uniform, and warmed in a hot water bath until the egg liquid reached about 25 ° C. This was whipped with a universal stirrer and whipped until no more was bubbled. To this, B was mixed so as not to knead, placed in a sponge cake mold, and baked in an oven at 160 ° C. for 40 minutes. The formulation of this example includes 70 g palatinose, 30 g sucrose, and about 90 g starch.

(Example 10)
<Soft drinks containing palatinose and isomerized sugar>
Soft drinks containing palatinose and isomerized sugar were prepared with the formulation shown in Table 13 below. The following raw materials were dissolved in 250 ml of hot water and then filled into beverage cans (for 250 ml).

(Example 11)
<Madeleine containing palatinose and starch>
Madeleine containing palatinose and starch was prepared according to the formulation shown in Table 14 below. The flour and baking powder were sifted together. The butter was melted in a hot water bath. Eggs were placed in a bowl, and granulated sugar, salt, lemon peel, and lemon essence were added to the water bath. While warming, palatinose was added and stirred well with a whisk. Sifted flour was added all at once, mixed well, and melted butter was added and mixed. Separated into aluminum foil cups and baked in an oven at 160 ° C. for about 10 minutes until colored. The Madeleine obtained according to this example contains 60 g palatinose and about 37 g starch.

Example 12
<Cake mix containing palatinose, sucrose, and flour>
A cake mix was prepared with the formulation shown in Table 15 below. Materials other than the shortening were premixed, and the shortening dissolved therein was mixed and sieved.

(Example 13)
<Hotcake mix containing palatinose and flour>
Powder mixing was performed with the formulation shown in Table 16 below to prepare a hot cake mix. Materials other than shortening were premixed, dissolved shortening was added, mixed, and then sieved.

Claims (5)

  A preventive or ameliorating agent for metabolic syndrome comprising isomaltulose as an active ingredient.   The preventive or ameliorating agent according to claim 1, which is used for the prevention and improvement of hypertension.   The preventive or ameliorating agent according to claim 1, which is used for the prevention and improvement of serum lipid abnormality.   The preventive or ameliorating agent according to any one of claims 1 to 3, wherein 7 to 40 g / day is administered as the isomaltulose content.   The preventive or ameliorating agent according to claim 4, which is administered for 3 months or more.